利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

23 条记录 (耗时 0.018 秒)

    Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
    13.
    发明公开
    Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions 有权
    WasserlöslicheStrontiumsalze zur Behandlung von Knorpel- und Knochenerkrankungen

    公开(公告)号：EP2266585A2

    公开(公告)日：2010-12-29

    申请号：EP10185891.8

    申请日：2004-05-06

    申请人： Osteologix A/S

    发明人： Christgau, Stephan ,  Hansen, Christian ,  Andersen, Jens ,  Nilsson, Henrik

    IPC分类号： A61K33/24 ,  A61P19/08

    CPC分类号： A61K33/24 ,  C07C55/08 ,  C07C55/10 ,  C07C57/145 ,  C07C59/08 ,  C07C59/19 ,  C07C59/347

    摘要： Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such conditions. The compounds are salts of strontium that have a water-solubility of from about 1 g/I to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate.
    The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

    摘要翻译： 用于治疗和/或预防软骨和/或骨骼状况的化合物和药物组合物以及治疗这些病症的方法。 这些化合物是在室温下具有约1g / l至约100g / l水溶性的锶盐，特别是锶的锶或二羧酸盐的氨基酸盐。 新的水溶性锶盐的实例是例如。 谷氨酸锶和α-酮戊二酸锶。 本发明还涉及一种制备谷氨酸锶盐的改进方法。

    STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS
    20.
    发明授权
    STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS 有权
    STR GE GE N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N N

    公开(公告)号：EP1732575B1

    公开(公告)日：2010-12-29

    申请号：EP05706802.5

    申请日：2005-02-28

    申请人： Osteologix A/S

    发明人： HANSEN, Christian ,  NILSSON, Henrik ,  CHRISTGAU, Stephan ,  BONE, Henry, G., III

    IPC分类号： A61K33/24 ,  A61K31/28 ,  A61K31/663 ,  A61K31/56 ,  A61K31/57 ,  A61K45/06 ,  A61P19/08

    CPC分类号： A61K33/24 ,  A61K31/28 ,  A61K31/56 ,  A61K31/57 ,  A61K31/663 ,  A61K45/06 ,  A61K2300/00

    摘要： A method for the treatment and/or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).

    摘要翻译： 用于治疗和/或预防有需要的哺乳动物中的恶性坏死性骨病的方法，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死，Legg-Calve-Perthes疾病和股骨 头坏死，所述方法包括向哺乳动物施用有效剂量的含锶化合物（a）。 用于治疗和/或预防要治疗或治疗的哺乳动物的骨坏死性骨病，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死和股骨头坏死的方法 具有已知或怀疑诱导骨细胞凋亡和/或坏死的治疗剂（b），该方法包括与（b）组合施用含锶化合物（a）。